

**DXC Technology Scandihealth A/S**  
**Company Registration No 25 46 93 64**  
**Dusager 25**  
**8200 Aarhus N.**

**Annual Report 2020/21**  
**(1 April 2020 – 31 March 2021)**

The annual report is presented and adopted on the Annual General Meeting on 17<sup>th</sup> September 2021

**Chairman of the Annual General Meeting**

Sylvie Pasque

# DXC Technology Scandihealth A/S

## Contents

---

|  | <b>Page</b> |
|--|-------------|
| Company detail   | 1           |
| Management's statement   | 2           |
| Independent auditor's report   | 3           |
| Management report  | 6           |
| Accounting policies  | 10          |
| Income statement for the financial year 1 April 2020 – 31 March 2021 | 15          |
| Balance sheet as at 31 March 2021                                    | 16          |
| Statement of changes in equity for 1 April 2020 – 31 March 2021      | 18          |
| Notes  | 19          |

# **DXC Technology Scandihealth A/S**

## **Company details**

---

### **Company**

DXC Technology Scandihealth A/S

Company Registration No: 25 46 93 64

Municipality of domicile: Aarhus

Phone: +45 3614 4000

Fax: +45 3614 7324

Internet: [www.dxc.technology/dk](http://www.dxc.technology/dk)

E-mail: [scandihealth@dxc.com](mailto:scandihealth@dxc.com)

### **Board of Directors**

Jørgen Jakobsen, Chairman

Peter Winther-Schmidt

Felora Mofidi

### **Executive Board**

Peter Winther-Schmidt

### **Company auditors**

Deloitte Statsautoriseret Revisionspartnerselskab

Weidekampsgade 6

2300 København S

## **DXC Technology Scandihealth A/S**

### **Management's statement**

---

The Board of Directors and the Executive Board have today considered and approved the annual report of DXC Technology Scandihealth A/S for the financial year 1 April 2020 to 31 March 2021.

The annual report is presented in accordance with the Danish Financial Statements Act.

In our opinion the financial statements give a true and fair view of the Company's financial position at 31 March 2021 and of its financial performance for the financial year 1 April 2020 – 31 March 2021.

We believe that the management report contains a fair review of the affairs and conditions referred to therein.

We recommend the annual report for adoption at the Annual General Meeting.

Copenhagen, 17<sup>th</sup> September 2021

#### **Executive Board**

---

Peter Winther-Schmidt  
Managing Director

#### **Board of Directors**

---

Jørgen Jakobsen  
Chairman

---

Peter Winther-Schmidt

---

Felora Mofidi

# **DXC Technology Scandihealth A/S**

## **Independent auditor's report**

---

### **To the shareholder of DXC Technology Scandihealth A/S**

#### **Opinion**

We have audited the financial statements of DXC Technology Scandihealth A/S for the financial year 1 April 2020 – 31 March 2021 which comprise a summary of significant accounting policies, the income statement, balance sheet, statement of changes in equity and notes. The financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the Entity's financial position at 31 March 2021 and of the results of its operations for the financial year 1 April 2020 – 31 March 2021 in accordance with the Danish Financial Statements Act.

#### **Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the *Auditor's responsibilities for the audit of the financial statements* section of this auditor's report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### **Management's responsibilities for the financial statements**

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Entity's ability to continue as a going concern, for disclosing, as applicable, matters related to going concern, and for using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Entity or to cease operations, or has no realistic alternative but to do so.

#### **Auditor's responsibilities for the audit of the financial statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

## **DXC Technology Scandihealth A/S**

### **Independent auditor's report (continued)**

---

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Entity's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.
- Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements, and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Entity to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures in the notes, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

## **DXC Technology Scandihealth A/S**

### **Independent auditor's report (continued)**

---

#### **Statement on the management commentary**

Management is responsible for the management commentary.

Our opinion on the financial statements does not cover the management commentary, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the management commentary and, in doing so, consider whether the management commentary is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether the management commentary provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that the management commentary is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of the management commentary.

Copenhagen, 17<sup>th</sup> September 2021

#### **Deloitte**

Statsautoriseret Revisionspartnerselskab  
Business Registration No 33 96 35 56

Eskild Nørregaard Jakobsen  
State-Authorised  
Public Accountant  
MNE no: 11681

# DXC Technology Scandihealth A/S

## Management report

---

### Financial highlights

#### Key figures

|  | <b>2020/21</b> | <b>2019/20</b> | <b>2018/19</b> | <b>2017/18</b> | <b>2016/17</b> |
|--|----------------|----------------|----------------|----------------|----------------|
|  | <b>DKK'000</b> | <b>DKK'000</b> | <b>DKK'000</b> | <b>DKK'000</b> | <b>DKK'000</b> |
| Revenue  | 237,499        | 170,551        | 257,664        | 406,268        | 467,010        |
| Earnings/(loss) from operating activities                      | (8,265)        | (420,859)      | (166,346)      | (47,361)       | (34,581)       |
| Net financials   | (299)          | (5,165)        | (4,022)        | (556)          | (591)          |
| Profit/(loss) for the year                                     | (8,563)        | (422,569)      | (164,411)      | (46,736)       | (30,147)       |
| Equity   | 68,586         | 77,148         | (283)          | 164,128        | 460,864        |
| Balance sheet total  | 99,875         | 197,765        | 494,122        | 503,403        | 600,735        |
| Investment in property, plant & equipment and intangible asset | 373            | 789            | 1,946          | 978            | 2,588          |
| Average operating assets**                                     | 148,820        | 345,944        | 498,762        | 453,663        | 369,227        |
| <b>Ratios*</b>   |                |                |                |                |                |
| Operating margin (%)   | (3.5)          | (246.8)        | (64.6)         | (11.7)         | (7.4)          |
| Return on operating assets (%)                                 | (5.6)          | (121.7)        | (33.4)         | (10.4)         | (9.4)          |
| Return on equity (%)   | (0.1)          | (11.0)         | (2.0)          | (0.1)          | (0.1)          |
| Equity share (%)   | 68.7           | 39.0           | (0.1)          | 32.6           | 76.7           |

\*Key ratios are calculated in accordance with the current version of “The Danish Society of Financial Analysts recommendations & Financial Ratios”



## **DXC Technology Scandihealth A/S Management report (continued)**

---

### **Core business activity**

DXC Technology Scandihealth A/S's core business is the development and sales of IT solutions for the health and social sector.

### **Development of activities and financial matters**

#### **Result for the year**

The result includes increase in revenue by 39% compared to last year. Revenue came in at 237.5 DKKm with a loss after tax of 8.6 DKKm.

#### **Evaluation of last year's expectations**

In the Annual Report for 2020/21, the expectation was to keep the current market share within the Healthcare area for IT solutions and improve the level of result before tax. The expectations for 2020/21 have been met. We have managed to increase our revenue, while at the same time decreasing our costs, compared to last year.

#### **Investments**

As the intend for most of the financial year have been to sell a large part of the company, the focus has not been on further investments.

#### **Financial resources**

As of 31 March 2021, the Company's equity position was 68.1 DKKm, resulting in the equity ratio has increased to 68.7 (in 2020/21) from 39.0 (in 2019/20).

The ultimate parent company has issued a letter of support to ensure that the Company will have sufficient capital resources.

#### **Events after the balance sheet day / discontinued activity**

After year end DXC Technology has concluded the agreement to sell DXC's healthcare business, which includes a significant part of the activity of DXC Tecnology Scandihealth A/S to the Dedalus Group. The transaction has resulted in a minor profit on April 1st 2021. Management intends to merge the company with the parent company DXC Technology Danmark A/S within a few years.

## **DXC Technology Scandihealth A/S Management report (continued)**

---

### **Special risks**

#### **Risk management policy**

As a result of its operations and financing, the Company is exposed to a number of financial risks e.g. changes in currency and interest rates, liquidity risks and credit risks. Management of financial risks is centralized and handled by the parent company DXC Technology Danmark A/S. The general framework for financial risk management is determined in the DXC Technology Group's finance policy which is applicable to all DXC Technology entities worldwide.

#### **Operational risks**

The Company's most significant operational risk is related to its ability to be price competitive as well as deliver solutions to clients who demand a highly qualified workforce. It is thus essential that the workforce is continuously molded to fit the actual demands of clients. Furthermore, it is important that the Company continuously innovates in order to be on the forefront in terms of the IT systems used in the health- and social sector.

#### **Market risks**

The Company's most significant market risk is tied to its ability to be strongly positioned within the important Nordic markets in which it primarily operates.

#### **Currency risks**

The Company invoices primarily in DKK and the bulk of the costs for salary and other external costs are also incurred in DKK.

#### **Interest risks**

Changes in interest rates will have a moderate and indirect effect on the Company's earnings, due to the Company's involvement in the Group's cash pool scheme.

#### **Liquidity risks**

The Company is dependent on having access to long-term financing. This is why the Company adheres to the policy of having interminable credit limits that are sufficient to cover the planned operations.

The Company is only exposed to the changes in interest rates. The Company's financial resources are comprised of cash and cash equivalents and unutilized credit facilities within these. Cash pools have been established in the relevant currencies, which for the Company relates to DKK.

#### **Credit risks**

Credit risks tied to financial assets relate to those values which are calculated in the company's balance sheet. The Company has no significant risks related to or dependence of one customer or business partner.

Historically, the Company has only incurred small losses on receivables which also applies to the current fiscal year.

## **DXC Technology Scandihealth A/S**

### **Management report (continued)**

---

#### **Risk on COVID-19**

In relation to COVID-19, Management continue to monitor the effects of the outbreak globally and the potential impact on the business. The outbreak increases uncertainty about the future prospects of the company. However, senior leadership in DXC is actively managing the Company's response through a COVID-19 Response Team that meets on a daily basis to deal with all operational issues as and when they arise. Management is actively taking steps to ensure the protection and retention of staff and the associated corporate memory that are crucial to the company's ability to weather this crisis and to rebuild when the opportunity arises.

#### **Intellectual capital property**

The company's business model seeks to create value for clients by delivering healthcare IT solutions which are adaptable to future needs. This makes large demands on knowledge-based resources and business processes.

In order to be able to deliver these solutions, it is paramount that the Company is able to recruit and retain individuals who are highly educated within IT solutions for the health- and social sector.

#### **Research and development**

The company development activities relate primarily to the development of IT solutions for the healthcare and social sector.

This year, the focus has been on dedicated development plans of new IT solutions. These plans are to ensure that there is a strategic fit between the Company's activities and the demands from the market, so that the Company's new and innovative IT products and solutions can be brought to the market and our clients as fast as possible.

## **DXC Technology Scandihealth A/S**

### **Accounting policies**

---

This annual report for DXC Technology Scandihealth A/S for the financial year 2020/21 has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C (medium), with the addition of certain provisions for reporting class C (large).

The accounting policies applied to these financial statements are consistent with those applied last year, with the exception of the comparison figures, as DXC Technology Scandihealth A/S has made a number of reclassifications. However, the changes have had no effect on the total assets, liabilities, financial position and results of its operations.

In accordance with provision 86, 4 of the Danish Financial Statements Act, DXC Technology Scandihealth A/S has omitted to prepare a cash flow statement as the cash flow is part of the cash flow statement for the group annual report for DXC Technology Company, Tysons, Virginia, USA.

#### **Recognition and measurement**

Assets are recognized in the balance sheet when it is probable that – as a result of a prior event – future economic benefits will flow to the Company, and the value of the assets can be measured reliably.

Liabilities are recognized in the balance sheet when the Company has a legal or constructive obligation as a result of a prior event, and it is probable that future economic benefits will flow out of the Company, and the value of the liabilities can be measured reliably.

On initial recognition, assets and liabilities are measured at cost. Measurement subsequent to initial recognition is effected as described below for each financial statement item.

Financial assets and liabilities are measured on the basis of amortized cost – within which a fixed interest rate is used. Amortized cost is calculated as the purchase price inclusive of any accumulated amortized additions/deductions of the difference between the cost price and the nominal value.

Anticipated risks and losses that arise before the time of presentation of the annual report and that confirm or invalidate affairs and conditions existing at the balance sheet date are considered at recognition and measurement.

Income hereunder valuation adjustments of financial assets and liabilities measured at fair value or amortized cost is recognized in the income statement when earned. Costs that have been incurred in order to generate earnings are recognized in the income statement hereunder depreciation, write downs, provisions.

#### **Foreign currency translation**

On initial recognition, foreign currency transactions are converted by applying the exchange rate as at the transaction date. Exchange differences that arise between the rate at the transaction date and the one in effect at the payment date or the rate at the balance sheet date are recognized in the income statement as financial income or financial expenses.

Receivables, payables and other monetary items denominated in foreign currencies that have not been settled at the balance sheet date are converted using the exchange rate at the balance sheet date. The difference between the spot exchange rate and the date when the receivable or liability is realized, is recognized in the income statement under financial income and expenses.

Property, plant and equipment, intangible assets and other non-monetary assets that have been purchased in foreign currencies are translated using historical rates.

## **DXC Technology Scandihealth A/S**

### **Accounting policies (continued)**

---

#### **Income statement**

##### **Revenue**

Revenue from the sale of services is recognized in the income statement when delivery is made, risk has transferred to the buyer, if the revenue can be calculated reliably and it is expected that payment is received. Revenue is recognized net of VAT, duties and sales discounts and is measured at fair value of the fixed consideration net of VAT and duties charged on behalf of a third party.

Contract work in progress is included in revenue based on the stage of completion so that revenue corresponds to the selling price of the work performed in the financial year (the percentage-of-completion method).

##### **Other external expenses**

Other external expenses include expenses for distribution, sale, marketing, administration, premises, loss on bad debts etc.

Other external expenses also include research costs and costs of development projects that do not meet the criteria for recognition in the balance sheet. In addition, provisions for loss on contract work in progress are recognized.

##### **Personnel expenses**

Personnel expenses include salaries and wages as well as social insurance contributions, pension contributions etc. for the company's employees.

##### **Depreciation, amortisation and impairment losses**

Depreciation, amortisation and impairment losses relating to plant and equipment and intangible assets comprise depreciation, amortisation and impairment losses for the financial year.

##### **Financial income and expenses**

These items include interest income and expenses, realized and unrealized capital gains and losses on payables and transactions in foreign currencies etc. as well as tax surcharge and tax relief under the Danish Tax Prepayment scheme.

##### **Income tax**

Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognized in the income statement by the portion attributable to the profit for the year and recognized directly in equity by the portion attributable to entries directly in equity.

##### **Balance sheet**

##### **Intangible assets**

Intangible assets are comprised of in-progress and completed development projects with related intellectual property rights, acquired intellectual property rights and prepayments for intangible assets.

Development projects on clearly defined and identifiable products and processes, for which the technical rate of utilization, adequate resources and a potential future market or development opportunity in the enterprise can be established, and where the intention is to manufacture, market or apply the product or process in question, are recognized as intangible assets, if the cost price can be reliably measured and there is sufficient security that the future earnings are greater than other external expenses as well as development costs. Other development costs are recognized as costs in the income statement as incurred.

## **DXC Technology Scandihealth A/S**

### **Accounting policies (continued)**

---

#### **Intangible assets (continued)**

The cost of development projects includes salaries that are directly and indirectly attributable to the company's development activities.

Completed development projects recognized in the balance sheet are measured at cost less accumulated amortization and impairment losses.

Completed development projects are amortized on a straight-line basis using the estimated useful lives of the assets. The amortization period is usually seven years.

The lifetime for newly developed products is evaluated in conjunction with the start-up of a new development project. When existing products are developed further by adding new modules and functionalities, a reevaluation of the entire products expected useful lifetime is performed, including the existing product, at the end of the fiscal year.

Acquired intellectual property rights in the form of licenses are measured at cost less accumulated amortization and impairment losses. Licenses are amortized over the term of the agreement.

Profits and losses from the sale of development projects and licenses are calculated as the difference between selling price less selling costs and the carrying amount at the time of sale. Profits and losses are recognized in the income statement as an adjustment to amortisation and impairment losses, or under other income.

#### **Property, plant and equipment**

Plant and machinery, other fixtures and fittings, tools and equipment and leasehold improvements are measured at cost less accumulated depreciation and impairment losses.

Costs include the acquisition price, costs directly attributable to the acquisition, and preparation costs of the asset until the time when it is ready to be put into operation.

The basis of depreciation is cost less estimated residual value after the end of useful life. Straight-line depreciation is made on the basis of the following estimated useful lives of the assets:

|   |            |
|---|------------|
| Plant and machinery                     | 5-7 years  |
| Other fixtures and fittings, tools etc. | 5-10 years |
| Leasehold                               | 1-5 years  |

Profits and losses from the sale of property, plant and equipment are calculated as the difference between selling price minus selling costs and carrying amount at the time of sale. Profits or losses are recognized in the income statement as adjustment to depreciation and impairment losses, or under other operating income if the selling price exceeds original cost.

#### **Devaluation of fixed assets**

The accounting value of intangible and fixed assets is evaluated yearly for indications of a decrease in value over and above that caused by depreciation and amortization.

If it becomes apparent that assets devalue, an impairment test is made of each and every asset or asset class. Assets are written down to the recoverable amount and carrying amount.

## **DXC Technology Scandihealth A/S**

### **Accounting policies (continued)**

---

#### **Receivables**

Receivables are measured at amortized cost, usually equaling nominal value.

A write down to counter to receivables will be performed if there are objective indications that the receivable or portfolio of receivables have devalued. If a single receivable is deemed to have devalued, then the write down will be undertaken on an individual receivable.

Write downs are calculated as the difference between the accounting value of receivables and the present value of the expected cash flows, hereunder the realized value of any received collateral. The discount rate used is the effective rate for each specific receivable or portfolio.

#### **Contract work in progress**

Contract work in progress is measured at the selling price of the work carried based on the stage of completion.

The stage of completion is determined as the ratio between actual and total budgeted costs on each project.

When it is probable that total costs incurred on each project will exceed total income on the project, expected loss is recognized in the income statement.

On account invoices are deducted in the sales value. Each contract in progress is recognized as a receivable when the net value is positive and as a liability when prepayments exceed the sales value.

Sales promotion costs and costs related to obtaining the contracts are recognized in the income statement concurrently with the incurred costs.

#### **Prepayments**

Prepayments disclosed as current assets include incurred costs relating to subsequent financial years. Prepayments are measured at cost.

Costs for conclusion of outsourcing contracts are recognized in prepayments and amortized over the contract period.

#### **Tax payable and deferred tax**

The current tax payable or receivable is recognized in the balance sheet, stated as tax calculated on this year taxable income, adjusted for prepaid tax.

Deferred tax is recognized on all temporary differences between the carrying amount and tax-based value of assets and liabilities, for which the tax-based value of assets is calculated based on the planned use of each asset.

Deferred tax assets, including the value of the carried forward taxable losses, are recognized in the balance sheet at their estimated realisable value, either to off-set future taxable income or deferred tax liabilities within the same legal entity or jurisdiction.

The company has entered into a joint taxation agreement. The actual Danish corporate tax is divided between the jointly taxed companies in proportion to their taxable income (distribution with reimbursement on losses).

## **DXC Technology Scandihealth A/S**

### **Accounting policies (continued)**

---

#### **Provisions**

Provisions are recognized when the Company has a present obligation, either legal or constructive, as a result of a past event, it is probable that the Group will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation.

The amount recognized is the best estimate of the consideration required to settle the present obligation at the end of each reporting period, taking into account the risks and uncertainties surrounding the obligation. When a provision is measured using the cash flows estimated to settle the present obligation; its carrying amount is the present value of those cash flows.

When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, the receivable is recognized as an asset if it is virtually certain that reimbursement will be received and the amount of the receivable can be measured reliably.

Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate.

If it is no longer probable that a transfer of economic benefits will be required to settle the obligation, the provision should be reversed.

#### **Other liabilities**

Financial liabilities which include trade payables and liabilities to other group entities are measured at amortized cost which usually corresponds to nominal value.

#### **Deferred income**

Deferred income disclosed as short-term liabilities includes received income for recognition in subsequent financial years. Deferred income is measured at cost.

#### **Financial highlights**

The definition of key ratios is in accordance with current version of "The Danish Society of Financial Analysts Recommendations & Financial Ratios"

$$\text{Operating margin (\%)} = \frac{\text{Earnings from operating act. x}}{100} \text{ Revenue}$$

$$\text{Return on operating assets (\%)} = \frac{\text{Earnings from operating act. x}}{100} \text{ Average operating assets}$$

$$\text{Return on equity (\%)} = \frac{\text{Profit/loss for the year x 100}}{\text{Average equity}}$$

$$\text{Equity share (\%)} = \frac{\text{Equity x 100}}{\text{Total assets}}$$

Operating assets = Operating assets are total assets less Cash.



**DXC Technology Scandihealth A/S**  
**Income statement for the financial year 1 April 2020 - 31 March 2021**

---

|   | Note | <u>2020/21</u><br><u>DKK'000</u> | <u>2019/20</u><br><u>DKK'000</u> |
|---|------|----------------------------------|----------------------------------|
| Revenue                                   |      | 237,499                          | 170,551                          |
| Other external expenses                   |      | (176,943)                        | (415,087)                        |
| Other operating income                    |      | 9,650                            | -                                |
| <b>Gross profit</b>                       |      | <b>70,206</b>                    | <b>(244,536)</b>                 |
| Personnel expenses                        | 1    | (73,622)                         | (78,704)                         |
| Depreciation, amortization and impairment | 4-5  | (4,849)                          | (97,619)                         |
| <b>Losses from operating activity</b>     |      | <b>(8,265)</b>                   | <b>(420,859)</b>                 |
| Financial expenses                        |      | (299)                            | (5,165)                          |
| <b>Loss before income tax</b>             |      | <b>(8,564)</b>                   | <b>(426,024)</b>                 |
| Income tax                                | 2    | -                                | 3,455                            |
| <b>Loss for the year</b>                  |      | <b>(8,564)</b>                   | <b>(422,569)</b>                 |
| <b>Proposed distribution of loss</b>      | 3    |                                  |                                  |

**DXC Technology Scandihealth A/S**  
**Balance sheet as at 31 March 2021**

| Assets   | Note | 2021<br>DKK'000       | 2020<br>DKK'000       |
|--|------|-----------------------|-----------------------|
| Completed development projects                   |      | 38,389                | 41,021                |
| Acquired licenses                                |      | 205                   | 766                   |
| <b>Intangible assets</b>                         | 4    | <u><b>38,594</b></u>  | <u><b>41,787</b></u>  |
| Plant and machinery                              |      | 2,613                 | 3,847                 |
| Other fixtures and fittings, tools and equipment |      | 16                    | 158                   |
| Leasehold improvements                           |      | -                     | 160                   |
| <b>Property, plant and equipment</b>             | 5    | <u><b>2,629</b></u>   | <u><b>4,165</b></u>   |
| Other receivables                                |      | 1,937                 | 4,702                 |
| <b>Financial assets</b>                          | 6    | <u><b>1,937</b></u>   | <u><b>4,702</b></u>   |
| <b>Non-current assets</b>                        |      | <u><b>43,160</b></u>  | <u><b>50,654</b></u>  |
| Trade receivables                                |      | 36,489                | 90,972                |
| Contract work in progress                        | 7    | 2,135                 | 7,251                 |
| Other receivables                                |      | 5,107                 | 6,160                 |
| Prepayments                                      | 8    | 5,897                 | 6,362                 |
| Group entity receivables                         | 13   | 11,688                | 36,366                |
| <b>Receivables</b>                               |      | <u><b>61,316</b></u>  | <u><b>147,111</b></u> |
| <b>Current assets</b>                            |      | <u><b>61,316</b></u>  | <u><b>147,111</b></u> |
| <b>Assets</b>                                    |      | <u><b>104,476</b></u> | <u><b>197,765</b></u> |

**DXC Technology Scandihealth A/S**  
**Balance sheet as at 31 March 2021 (continued)**

| <b>Liabilities</b>                 | <b>Note</b> | <b>2021</b><br><b>DKK'000</b> | <b>2020</b><br><b>DKK'000</b> |
|------------------------------------|-------------|-------------------------------|-------------------------------|
| Share capital                      | 9           | 25,000                        | 25,000                        |
| Reserve for development projects   |             | 38,389                        | 41,021                        |
| Retained earnings                  |             | 5,196                         | 11,127                        |
| <b>Equity</b>                      |             | <b>68,584</b>                 | <b>77,148</b>                 |
| Other payables                     |             | 7,192                         | 4,833                         |
| <b>Non-current liabilities</b>     |             | <b>7,192</b>                  | <b>4,833</b>                  |
| Trade payables                     |             | 1,598                         | 2,736                         |
| Group entity payables              |             | 3,965                         | 51,267                        |
| Other payables                     |             | 17,524                        | 47,852                        |
| Deferred income                    | 11          | 5,613                         | 13,929                        |
| <b>Current liabilities</b>         |             | <b>28,700</b>                 | <b>115,784</b>                |
| <b>Total Liabilities</b>           |             | <b>35,892</b>                 | <b>120,617</b>                |
| <b>Equity and liabilities</b>      |             | <b>104,476</b>                | <b>197,765</b>                |
| Contingencies and commitments etc. |             | 12                            |                               |
| Loans and collateral               |             | 13                            |                               |
| Related parties                    |             | 14                            |                               |
| Financial resources                |             | 15                            |                               |
| Subsequent events                  |             | 16                            |                               |

**DXC Technology Scandihealth A/S**  
**Statement of changes in equity for 1 April 2020 – 31 March 2021**

|                                   | Share capital        | Reserve for<br>development<br>projects | Retained<br>earnings | Total                |
|-----------------------------------|----------------------|--|----------------------|----------------------|
|                                   | <u>DKK'000</u>       | <u>DKK'000</u>                         | <u>DKK'000</u>       | <u>DKK'000</u>       |
| Equity as at 1 April 2020         | 25,000               | 41,021                                 | 11,127               | 77,148               |
| Development projects reserve      | -                    | (2,631)                                | 2,631                | -                    |
| Loss for the year                 | -                    | -                                      | (8,564)              | (8,564)              |
| <b>Equity as at 31 March 2021</b> | <b><u>25,000</u></b> | <b><u>38,390</u></b>                   | <b><u>5,194</u></b>  | <b><u>68,584</u></b> |

# DXC Technology Scandihealth A/S

## Notes

### 1. Personnel expenses

|  | <b>2020/21</b> | <b>2019/20</b> |
|--|----------------|----------------|
|  | <b>DKK'000</b> | <b>DKK'000</b> |
| Salaries and services  | 67,942         | 74,164         |
| Pension costs  | 5,057          | 6,175          |
| Capitalized personnel expenses   | -              | (2,431)        |
| Other social insurance contributions   | 623            | 796            |
|  | <b>73,622</b>  | <b>78,704</b>  |
| <br>   |                |                |
| Total compensation and remuneration to the<br>Managing director and Board of directors | <b>1,984</b>   | <b>3,139</b>   |
| <br>   |                |                |
| Average number of employees  | <b>98</b>      | <b>120</b>     |

Management is employed in and remunerated by other entities within the DXC Group. The amount disclosed above is an allocation based on an estimate of management's time consumption.

In accordance with provision 98 b, 3 of the Danish Financial Statements Act the remuneration of the Managing Director and Board of Directors is disclosed as a combined amount.

The reorganization costs in current year is 4,407 DKK'000 (2019/20: 3,022DKK'000).

### 2. Income taxes

|                                  | <b>2020/21</b> | <b>2019/20</b> |
|----------------------------------|----------------|----------------|
|                                  | <b>DKK'000</b> | <b>DKK'000</b> |
| Current tax                      | 0              | (3,455)        |
| Change in deferred tax last year | (12,062)       | (788)          |
| Change in deferred tax           | (5,193)        | (79,496)       |
| Not recognized part of tax asset | 17,255         | 80,284         |
|                                  | <b>0</b>       | <b>(3,455)</b> |

### 3. Proposed distribution of profit/loss

|                   | <b>2020/21</b> | <b>2019/20</b>   |
|-------------------|----------------|------------------|
|                   | <b>DKK'000</b> | <b>DKK'000</b>   |
| Loss for the year | (8,563)        | (422,569)        |
|                   | <b>(8,563)</b> | <b>(422,569)</b> |

**DXC Technology Scandihealth A/S**  
**Notes (continued)**

| <b>4. Intangible assets</b>                      | <b>Completed<br/>development<br/>projects<br/>DKK'000</b> | <b>Acquired<br/>licenses<br/>DKK'000</b> |
|--|---|--|
| Cost as at 01 April 2020                         | 306,941   | 4,524                                    |
| Additions  | 0   | -  |
| Disposal   | 0   | -  |
| <b>Cost as at 31 March 2021</b>                  | <b>306,941</b>  | <b>4,524</b>                             |
| Amortisation and impairment losses 01 April 2020 | (265,920)   | (3,758)                                  |
| Amortisation for the year                        | (17,631)  | (561)                                    |
| Reversal of impairment                           | 15,000  | -  |
| Amortisation and impairment losses 31 March 2021 | <b>(268,552)</b>  | <b>(4,319)</b>                           |
| <b>Carrying amount as at 31 March 2021</b>       | <b>38,389</b>   | <b>205</b>                               |

The company develops software to be sold to customers. The cost comprises primarily of man hours and is supported by estimates for future revenue and earnings.

The projects are evaluated on a yearly basis and this have resulted in a reversal of impairment of 15.0 m DKK (2019/20: 65.9 m DKK). The reversal of impairment is a result of sale of activity including development projects on April 1, 2021.

| <b>5. Property, plant &amp; equipment</b>                         | <b>Plant and<br/>machinery<br/>DKK'000</b> | <b>Other fixtures<br/>DKK'000</b> | <b>Leasehold<br/>improvements<br/>DKK'000</b> |
|---|--|-----------------------------------|---|
| Cost as at 01 April 2020  | 19,037                                     | 1,070                             | 518   |
| Additions   | 373  | -                                 | -   |
| Retirement  | (103)                                      | (932)                             | (518)   |
| <b>Cost as at 31 March 2021</b>                                   | <b>19,307</b>                              | <b>138</b>                        | <b>-</b>                                      |
| Depreciation and impairment losses as at 01 April 2020            | (15,190)                                   | (912)                             | (358)   |
| Depreciation for the year   | (1,607)                                    | (45)                              | (5)   |
| Depreciation reversals  | 103  | 835                               | 363   |
| <b>Depreciation and impairment losses as at<br/>31 March 2021</b> | <b>(16,694)</b>                            | <b>(122)</b>                      | <b>-</b>                                      |
| <b>Carrying amount as at 31 March 2021</b>                        | <b>2,613</b>                               | <b>16</b>                         | <b>-</b>                                      |

**6. Financial assets**

|   | <b>Other<br/>receivables<br/>DKK'000</b> |
|---|--|
| Cost as at 1 April 2020                               | 4,702                                    |
| Additions   | 40                                       |
| Disposals   | (2.805)                                  |
| <b>Cost as at 31 March 2021</b>                       | <b>1,937</b>                             |
| Depreciation and impairment losses as at 1 April 2020 | -  |
| Depreciation for the year                             | -  |
| <b>Carrying amount as at 31 March 2021</b>            | <b>1,937</b>                             |

**DXC Technology Scandihealth A/S**  
**Notes (continued)**

**7. Contract work in progress**

|                                       | <b>2021</b>    | <b>2020</b>    |
|---------------------------------------|----------------|----------------|
|                                       | <b>DKK'000</b> | <b>DKK'000</b> |
| Sales value of work performed         | 2,135          | 7,251          |
| Invoiced on account                   | -              | -              |
|                                       | <u>2,135</u>   | <u>7,251</u>   |
| The net value is recorded as follows: |                |                |
| Contract work in progress             | 2,135          | 7,251          |
| Prepayment from customers             | -              | -              |
|                                       | <u>2,135</u>   | <u>7,251</u>   |

**8. Prepayments**

Prepayments are made up of prepaid costs relating to personnel expenses as well as support and maintenance licenses.

**9. Share capital**

Share capital is made up of 25,000 shares at DKK 1,000 nominal value. The ordinary shares are not divided into classes.

|   | <b>2021</b>      | <b>2020</b>      |
|---|------------------|------------------|
|   | <b>DKK'000</b>   | <b>DKK'000</b>   |
| <b>10. Deferred tax</b>                                       |                  |                  |
| Deferred tax regards the following financial statement items: |                  |                  |
| Intangible assets   | 5,195            | 9,199            |
| Property, plant and equipment                                 | (3,832)          | (3,468)          |
| Transition cost   | -                | 11               |
| Accrued income  | -                | (312)            |
| Income tax losses carried forwards                            | (138,804)        | (125,616)        |
|   | <u>(137,441)</u> | <u>(120,186)</u> |
| Not recognized amounts  | 137,441          | 120,186          |
| <b>Carrying value 31 March 2021</b>                           | <u>-</u>         | <u>-</u>         |
| Deferred taxes 01 April 2020                                  | -                | -                |
| Impairment of taxes   | 120,186          | 39,902           |
| Change for the year   | 17,255           | 80,284           |
| <b>Deferred taxes 31 March 2021</b>                           | <u>-</u>         | <u>-</u>         |

**11. Deferred income**

Deferred income comprises of prepayments received from customers, which will be recognized as revenue in the next fiscal year.

## DXC Technology Scandihealth A/S Notes (continued)

### 12. Contingencies and commitments etc.

|           | <b>2021</b>           | <b>2020</b>           |
|-----------|-----------------------|-----------------------|
|           | <b><u>DKK'000</u></b> | <b><u>DKK'000</u></b> |
| 0-1 years | 3,935                 | -                     |
| 1-5 years | <u>-</u>              | <u>-</u>              |
|           | <b><u>3,935</u></b>   | <b><u>-</u></b>       |

The Company participates in a Danish joint taxation arrangement in which DXC Technology Danmark A/S serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Company is therefore liable from the financial year 2013 for income taxes etc. for the jointly taxed companies and from 1 July 2012 also for obligations, if any, relating to the withholding of tax on interest, royalties and dividend for the jointly taxed companies. The jointly taxed companies' total known net liability under the joint taxation arrangement is disclosed in the administration company's financial statements.

#### Cash pool

The Company's financial resources are comprised of cash and cash equivalents and unutilized credit facilities. Cash pools have been established in the relevant currencies (DKK, SEK, NOK & EUR).

### 13. Loans and collaterals

The company's cash is part of a joint Nordic Cash Pool and used as collateral for the debt to the banks in other Nordic companies.

### 14. Related parties

#### Related parties with a controlling interest

The following related parties have a controlling interest in DXC Technology Scandihealth A/S:

| Name                                  | Municipality of domicile | Basis of influence |
|---------------------------------------|--------------------------|--------------------|
| DXC Technology Danmark A/S            | Copenhagen, Denmark      | Danish parent      |
| DXC UK International Operations Ltd   | England                  | Parent             |
| DXC UK International Ltd              | England                  | Parent             |
| DXC UK International Services Ltd     | England                  | Parent             |
| DXC UK International Holdings Ltd     | England                  | Parent             |
| DXC Lux 6 S.a.r.l.                    | Luxembourg               | Parent             |
| DXC Luxembourg Holding S.a.r.l.       | Luxembourg               | Parent             |
| DXC Lux 5 S.a.r.l.                    | Luxembourg               | Parent             |
| DXC Luxembourg International S.a.r.l. | Luxembourg               | Parent             |
| Lux 1 Holding Company, Inc.           | Delaware, USA            | Parent             |
| DXC US International Inc.             | Nevada, USA              | Parent             |
| DXC Technology Company                | Tysons, Virginia, USA    | Ultimate parent    |



## DXC Technology Scandihealth A/S Notes (continued)

| Transactions with related parties   | 2021<br><u>DKK'000</u> | 2020<br><u>DKK'000</u> |
|---|------------------------|------------------------|
| Revenue regarding labor and services with related parties   | 2,930                  | 8,842                  |
| Costs regarding labor and services from related parties   | 120,733                | 153,619                |
| Receivable/Payable partially relates to a cash pool and partially<br>receivables and payables from ordinary transactions with related parties | 7,723                  | (14,901)               |
| For management remuneration, please refer to note 1   |                        |                        |

### Group ownership

DXC Technology Scandihealth A/S is included in the consolidated financial statements of DXC Technology Company, Tysons, Virginia, USA. The consolidated financial statements for DXC technology Company is available at [https://www.dxc.technology/investor\\_relations/insights/149093-2020\\_annual\\_report](https://www.dxc.technology/investor_relations/insights/149093-2020_annual_report).

### 15. Financial resources

The ultimate parent company has issued a letter of support to ensure that the Company will have sufficient capital resources.

### 16. Subsequent events and discontinued activity

In relation to COVID-19, Management continue to monitor the effects of the outbreak globally and the potential impact on the business.

After year end DXC Technology has concluded the agreement to sell DXC's healthcare business, which includes a significant part of the activity of DXC Tecnology Scandihealth A/S to the Dedalus Group. The transaction has resulted in a minor profit on April 1st 2021. Management intends to merge the company with the parent company DXC Technology Danmark A/S within a few years.

It is not possible to split continued and discontinued activity for the financial year 2020/21, therefore disclosures regarding discontinued activity has only been disclosed in the notes and in the management report.